Skip to Content

15 Results Found

  • Review
  • Open Access
1,767 Views
17 Pages

Botulinumtoxin Type-A (BoNTA) in the Management of Refractory Trigeminal Neuralgia: An Expert-Opinion, Practice-Oriented Narrative Review on Behalf of the GRASP Study Group

  • Andreas A. Argyriou,
  • Emmanouil V. Dermitzakis,
  • Dimitrios Rikos,
  • Georgia Xiromerisiou and ,
  • Panagiotis Soldatos,
  • Maria Chondrogianni,
  • Eleni Mavraki and
  • Michail Vikelis
  • + 3 authors+ 0 author

29 May 2026

Trigeminal neuralgia (TN) ranks among the most excruciating neuropathic pain syndromes, characterized clinically by multiple daily episodes of unilateral, paroxysmal, electric shock-like facial pain. The daily activities and quality of life of affect...

(This article belongs to the Special Issue Efficacy of Botulinum Toxin in Orofacial Pain)
  • Review
  • Open Access
19 Citations
10,921 Views
9 Pages

30 July 2021

There are few reports on the safety and effectiveness of long-term botulinumtoxin A (BoNT A) therapy in severe chronic pain of post-herpetic neuralgia (PHN). The literature was searched with the term “neuropathic pain” and “botulinum” on PubMed (up t...

(This article belongs to the Special Issue Advances in the Therapeutics of Neurological Diseases)
  • Review
  • Open Access

Botulinumtoxin als neue Option in der Behandlung der Depression

  • Samir Suker,
  • Kristina B. Rohde and
  • Gregor Hasler

Despite effective pharmacological and psychotherapeutic treatment options for depression, about one third of patients affected by depression prove resistant to therapy. The injection of botulinum toxin A (BTA) into the glabellar muscles of the forehe...

  • Article
  • Open Access
4 Citations
2,311 Views
10 Pages

Assessing the Use of BotulinumtoxinA for Hyperactive Urinary Tract Dysfunction a Decade After Approval: General Versus Local Anesthesia for BotulinumtoxinA Detrusor Injection

  • Heinrich Schulte-Baukloh,
  • Apostolos Apostolidis,
  • Catarina Weiss,
  • Thorsten Schlomm and ,
  • Sarah Weinberger,
  • Dirk Höppner,
  • Kathrin Haberecht,
  • Carsten Waskow,
  • Hendrik Borgmann and
  • Bernhard Ralla
  • + 6 authors+ 1 author

28 October 2024

Background: The onabotulinumtoxinA detrusor injection (OnabotA DI) was approved a decade ago for the treatment of patients with idiopathic overactive bladder (iOAB) or neurogenic detrusor overactivity (nDO) dysfunction who had not been treated succes...

(This article belongs to the Special Issue Botulinum Toxin for Urinary Tract Disease: After a Decade from Approval)
  • Article
  • Open Access
1 Citations
2,279 Views
16 Pages

A UK Single-Center, Retrospective, Noninterventional Study of Clinical Outcomes and Costs of Two BotulinumtoxinA Treatments for Limb Spasticity

  • Clive Bezzina,
  • Vadim Degtiar,
  • Natalya Danchenko,
  • Pascal Maisonobe and ,
  • Benjamin Davis,
  • Emanuel Engmann,
  • Elodie Guyon,
  • Sophie Lecanuet and
  • John Whalen
  • + 4 authors+ 0 author

30 August 2023

Service model changes at the North Staffordshire Rehabilitation Centre (UK) included switching spasticity treatment from onabotulinumtoxinA (onaBoNT-A) to abobotulinumtoxinA (aboBoNT-A). This noninterventional, retrospective, longitudinal study (NCT0...

  • Article
  • Open Access
1 Citations
2,461 Views
11 Pages

Assessing the Use of BotulinumtoxinA for Hyperactive Urinary Tract Dysfunction a Decade after Approval: A Single-Blind Study to Evaluate the Reduction in Pain in OnabotulinumtoxinA Detrusor Injection Using Different Injection Needles

  • Heinrich Schulte-Baukloh,
  • Catarina Weiss,
  • Thorsten Schlomm,
  • Sarah Weinberger and ,
  • Hendrik Borgmann,
  • Dirk Höppner,
  • Kathrin Haberecht and
  • Jörg Neymeyer
  • + 3 authors+ 0 author

14 September 2024

Overactive bladder (OAB) has a significant impact on the quality of life; thus, it requires treatment that can be adhered to over a long period without undue side effects. The current treatment which uses an anticholinergic or β-3 agonist may fa...

(This article belongs to the Special Issue Botulinum Toxin for Urinary Tract Disease: After a Decade from Approval)
  • Article
  • Open Access
7 Citations
6,164 Views
11 Pages

7 February 2022

Aim of this study was to investigate the long-term results of botulinum toxin A (BoNT-A) injections for the treatment of benign essential blepharospasm (BEB) and to report our experience with (ultra-)long-term treatment with onabotulinumtoxin-A. We c...

(This article belongs to the Special Issue Clinical Application of Botulinum Toxin)
  • Case Report
  • Open Access
3 Citations
2,188 Views
10 Pages

Targeted and Sequential Cryoneurolysis Improves Gait After Botulinum-Toxin Unresponsiveness in Post-Stroke Spasticity: A Laboratory-Verified Case

  • Frédéric Chantraine,
  • José Alexandre Pereira,
  • Céline Schreiber,
  • Tanja Classen and ,
  • Gilles Areno and
  • Frédéric Dierick
  • + 1 author+ 0 author

Background: Chronic post-stroke spasticity often limits gait despite best-practice botulinum-toxin intramuscular injections (BTIs), whose benefit is constrained by short duration, dose ceilings, and tachyphylaxis. Cryoneurolysis (CNL) induces a rever...

(This article belongs to the Section Movement Disorders and Neurodegenerative Diseases)
  • Article
  • Open Access
13 Citations
7,461 Views
9 Pages

Efficacy and Safety of a New Botulinum Toxin Type A Free of Complexing Proteins

  • Hyun-Mi Oh,
  • Joo Hyun Park,
  • Dae Heon Song and
  • Myung Eun Chung

24 December 2015

MT10107 is botulinum neurotoxin type A derived drug which utilizes the 150 kDa portion without complexing proteins and human serum albumin contents. To evaluate the efficacy and the safety of MT10107, it was compared with onabotulinumtoxinA in this d...

(This article belongs to the Section Bacterial Toxins)
  • Article
  • Open Access
10 Citations
7,082 Views
16 Pages

Safety Profile and Lack of Immunogenicity of IncobotulinumtoxinA in Pediatric Spasticity and Sialorrhea: A Pooled Analysis

  • Steffen Berweck,
  • Marta Banach,
  • Deborah Gaebler-Spira,
  • Henry G. Chambers and ,
  • A. S. Schroeder,
  • Thorin L. Geister,
  • Michael Althaus,
  • Angelika Hanschmann,
  • Matteo Vacchelli and
  • Edward Dabrowski
  • + 7 authors+ 2 authors

25 August 2022

IncobotulinumtoxinA, a pure botulinumtoxinA formulation, is free of accessory proteins. This analysis provides pooled safety data from phase 3 trials of children/adolescents (2–17 years), investigating incobotulinumtoxinA for the treatment of s...

(This article belongs to the Special Issue Emerging Botulinum Neurotoxins for Clinical Uses)
  • Review
  • Open Access
2 Citations
3,083 Views
11 Pages

13 October 2025

Using Medline and Scopus as search engines, we identified reports of 10 clinical studies (published up to 1 September 2025) on botulinum neurotoxin therapy for hereditary spastic paraplegia (HSP). Nine studies were conducted in adults and one in chil...

(This article belongs to the Special Issue Botulinum Toxin in Neuro-Rehabilitation: Expanding Horizons in Spasticity and Beyond)
  • Editorial
  • Open Access
1,181 Views
4 Pages

13 July 2025

Botulinum toxin was approved by the Food and Drug Administration in 2011 for neurogenic bladder and in 2013 for idiopathic overactive bladder (OAB) [...]

(This article belongs to the Special Issue Botulinum Toxin for Urinary Tract Disease: After a Decade from Approval)
  • Review
  • Open Access
1 Citations
2,147 Views
10 Pages

Botulinum Toxin Treatment of Stiff Person Syndrome—A Critical Review and Update

  • Ava Grace Tohidian,
  • Samira Marie Comtesse,
  • Shahroo Etemadmoghadam and
  • Bahman Jabbari

5 March 2026

Stiff person syndrome (SPS) is an autoimmune disorder with muscle stiffness and spasms, for which current therapies provide incomplete relief. Botulinum neurotoxin (BoNT) has been explored as an adjunctive symptomatic treatment. The aim of this revie...

(This article belongs to the Special Issue Botulinum Toxin: Advancing Treatments for Spasticity)
  • Review
  • Open Access
19 Citations
60,184 Views
15 Pages

Sustainable Dynamic Wrinkle Efficacy: Non-Invasive Peptides as the Future of Botox Alternatives

  • Trang Thi Minh Nguyen,
  • Eun-Ji Yi,
  • Xiangji Jin,
  • Qiwen Zheng and ,
  • Se-Jig Park,
  • Gyeong-Seon Yi,
  • Su-Jin Yang and
  • Tae-Hoo Yi
  • + 3 authors+ 0 author

Dynamic wrinkle reduction continues to challenge aesthetic dermatology, predominantly addressed through Botulinumtoxin (Botox) injections. Despite Botox’s robust efficacy with up to an 80% reduction in wrinkle visibility within just one week, i...

(This article belongs to the Special Issue 10th Anniversary of Cosmetics—Recent Advances and Perspectives)
  • Review
  • Open Access
102 Citations
25,251 Views
20 Pages

23 April 2013

Clinical features, anatomy and physiology of hyperhidrosis are presented with a review of the world literature on treatment. Level of drug efficacy is defined according to the guidelines of the American Academy of Neurology. Topical agents (glycopyrr...

(This article belongs to the Special Issue Neurotoxins: Health Threats and Biological Tools)